Aihara, Tomohiko http://orcid.org/0000-0003-2066-2522
Kumamaru, Hiraku
Ishitobi, Makoto
Miyashita, Minoru
Miyata, Hiroaki
Tamura, Kenji
Yoshida, Masayuki
Ogo, Etsuyo
Nagahashi, Masayuki
Asaga, Sota
Kojima, Yasuyuki
Kadoya, Takayuki
Aogi, Kenjiro
Niikura, Naoki
Iijima, Kotaro
Hayashi, Naoki
Kubo, Makoto
Yamamoto, Yutaka
Takeuchi, Yoshinori
Imoto, Shigeru
Jinno, Hiromitsu
Funding for this research was provided by:
Japanese Breast Cancer Society
Article History
Received: 28 July 2022
Accepted: 15 September 2022
First Online: 23 October 2022
Declarations
:
: HK reports receiving speaker fees from Chugai Pharmaceutical Co., Ltd and Johnson and Johnson KK, and consultation fees from Mitsubishi Tanabe Pharma and EP Croit Co., Ltd. HK is affiliated with the department of Healthcare Quality Assessment at the University of Tokyo. The department is a social collaboration department supported by National Clinical Database, Johnson and Johnson KK, Nipro corporation and Intuitive SĂ rl. YT reports receiving consultant fees from Pharmaceuticals and Medical Devices Agency and EPARK, Inc., and lecture fees from SAS Institute Japan Ltd. YT and HK are conducting a collaborative study with Pfizer inc., which is not related to the topic of this study.
: This is a database study. The use of the data for retrospective observational studies was approved by the ethics committee of National Clinical Database, and the Ethics Review Committee at the JBCS approved the study.Enquiries about data availability should be directed to the corresponding author.